The 21-valent pneumococcal conjugate vaccine (PCV21) elicited favorable immunogenicity and safety in infants and toddlers who were coadministered common pediatric vaccines, such as the measles, mumps, and rubella vaccine.

GLP-1 receptor agonists show promise in alleviating depressive symptoms in patients with type 2 diabetes, offering a potential dual benefit in treatment.

The treatment was generally well-tolerated in patients with ROS1-positive (ROS1+) non–small cell lung cancer (NSCLC).

HHS and Robert F. Kennedy Jr. prepare to unveil a report linking Tylenol use in pregnancy to autism, despite inconsistent study findings.

MM120 shows promise in treating generalized anxiety disorder, demonstrating significant symptom relief and a potential shift in psychiatric treatment approaches.

The 2 abstracts, which were presented at the European Society of Cardiology 2025 Congress, utilized data from the CDC WONDER database.

Research reveals how aging impacts flu severity in older adults, highlighting the need for enhanced vaccines and new therapeutic strategies.

Patritumab deruxtecan shows promising efficacy in HR+/HER2– metastatic breast cancer, meeting key trial end points and highlighting its potential for advanced treatment.

In combination with lipid-lowering therapy, inclisiran allowed patients with hypercholesterolemia to reach their low-density lipoprotein cholesterol (LDL-C) goals without associated muscle-related adverse events.

Host Craig Beavers sits down with Lorenz van der Linden, a Belgian pharmacist, to dive deep into 2 groundbreaking trials from the European Society of Cardiology (ESC) 2025 Congress.

Experts discuss radon—the second leading cause of lung cancer.

Plasma proteomics revolutionizes treatment for triple-negative breast cancer, offering predictive insights and new therapeutic strategies through the innovative PIPscore.

Health officials warn of rising Chagas disease cases in the US, linked to kissing bugs and the parasite Trypanosoma cruzi, urging public awareness.

The trial results, which showed baxdrostat significantly reduced mean seated systolic blood pressure in uncontrolled hypertension, were presented at the 2025 European Society of Cardiology Congress.

FDA expands Vonvendi use for von Willebrand disease (VWD), enhancing treatment options for adults and children to manage bleeding effectively.

RSV vaccination shows promise in reducing cardiorespiratory hospitalizations among older adults, highlighting potential heart and lung health benefits.

Both cemdisiran alone and combined with pozelimab improved the Myasthenia Gravis Activities of Daily Living score in patients with generalized myasthenia gravis.

Pavblu, a biosimilar to Eylea, also showed no clinically meaningful differences in efficacy, safety, and immunogenicity in patients with neovascular age-related macular degeneration (nAMD).

New research uncovers how smoking accelerates pancreatic cancer progression through immune mechanisms, revealing potential for targeted therapies and improved screening.

The FDA designates olomorasib as a breakthrough therapy, enhancing treatment options for advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutations.

September highlights Blood Cancer Awareness Month, focusing on education, early diagnosis, and support for multiple myeloma, lymphoma, and leukemia patients.

Following the European Society of Cardiology Congress 2025, experts gathered to discuss key Hot Line trial data.

Compared with docetaxel, adagrasib shows significant progression-free survival (PFS) benefits in patients with non–small cell lung cancer (NSCLC).

This milestone celebration not only honors CPA’s legacy but also underscores the profession’s future—one defined by collaboration, innovation, and a steadfast commitment to patient care.

FDA approves a new extended-release suspension formulation of risperidone for schizophrenia, expanding treatment options for patients.